The immune landscape of myelodysplastic syndromes.
Even though the pathogenesis of myelodysplastic syndromes (MDS) is dominated by specific molecular defects involving hematopoietic precursors, also immune mechanisms seem to play a fundamental functional role. In this review we will first describe the clinical and laboratory autoimmune manifestations often detectable in MDS patients. We will then focus on studies addressing the possible influence of different immune cell subpopulations on the disease onset and evolution. We will finally consider therapeutic approaches based on immunomodulation, ranging from immunosuppressants to vaccination and transplantation strategies.
Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy. Electronic address: cfozza@uniss.it.
Claudio
C
Fozza
Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Valeria
V
Crobu
Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Maria Antonia
MA
Isoni
Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Fausto
F
Dore
D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D059630:Mesenchymal Stem Cells / Q000276:immunology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D007166:Immunosuppressive Agents; D011948:Receptors, Antigen, T-Cell
Autoimmunity; Immunomodulating therapies; Myelodysplastic syndromes; T-cells